Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Rating of “Buy” by Brokerages

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) have received a consensus rating of “Buy” from the six analysts that are currently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $9.50.

QNCX has been the topic of several analyst reports. RODMAN&RENSHAW upgraded Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 29th. Rodman & Renshaw initiated coverage on Quince Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $11.00 price objective on the stock. Maxim Group initiated coverage on Quince Therapeutics in a research note on Thursday, November 7th. They issued a “buy” rating and a $6.00 price objective on the stock. D. Boral Capital reiterated a “buy” rating and issued a $12.00 price objective on shares of Quince Therapeutics in a research note on Wednesday, February 5th. Finally, Brookline Capital Management initiated coverage on Quince Therapeutics in a research note on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price objective on the stock.

Institutional Trading of Quince Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Anfield Capital Management LLC acquired a new stake in Quince Therapeutics in the fourth quarter valued at $50,000. Virtu Financial LLC acquired a new stake in Quince Therapeutics in the fourth quarter valued at $55,000. Two Sigma Investments LP acquired a new stake in Quince Therapeutics in the fourth quarter valued at $57,000. Northern Trust Corp raised its stake in Quince Therapeutics by 48.5% in the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after buying an additional 16,501 shares in the last quarter. Finally, Scharf Investments LLC acquired a new stake in Quince Therapeutics in the fourth quarter valued at $170,000. 30.75% of the stock is currently owned by institutional investors and hedge funds.

Quince Therapeutics Stock Up 1.4 %

NASDAQ:QNCX opened at $1.45 on Friday. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33. The stock’s fifty day moving average is $1.68 and its two-hundred day moving average is $1.31. Quince Therapeutics has a 52 week low of $0.51 and a 52 week high of $2.45. The stock has a market capitalization of $63.80 million, a price-to-earnings ratio of -1.17 and a beta of 0.61.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.